GRANULES

March 18 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT GRANULES EUROPE HAS BEEN VOLUNTARILY DISSOLVED

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];;))

** Shares of pharma co Granules India GRAN.NS fall 2.4% to 460 rupees

** Stock among top losers on Nifty Pharma index .NIPHARM

** The US FDA issued a warning letter to co post inspection

** Reports says bird droppings and feathers were found on air purification units, ducts, tank etc

** Flagged issues including lack of written procedures for equipment cleaning, residues and microbial contamination in ducts, risking cross-contamination

** More than 2.2 mln shares change hands, 1.6x its 30-day avg

** Stock down ~21% YTD vs a ~15% drop in NIPHARM

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

** Shares of Granules India GRAN.NS slide as much as 7% to 471.5 rupees, their lowest in eight months

** Stock last down 6.6%; biggest pct loser on Nifty pharma index .NIPHARM, which is down 1.3%

** Pharma co's Gagillapur facility gets US FDA warning letter based on inspection conducted in August 2024

** The warning letter may temporarily impact the FDA review of pending product submissions from this site until the issue is resolved - GRAN

** The U.S. FDA classified the facility as "official action indicated", sending its shares down over 10%, on December 3

** GRAN stock has fallen ~11% since December 3

** Four brokerages' avg rating on stock is "strong buy", median PT is 657.5 rupees - data compiled by LSEG

** Year-to-date, GRAN down 14%; Nifty pharma index also 14% lower

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

** Shares of Granules India GRAN.NS climb 2.2% to 520 rupees

** Pharma co says it signed agreement to acquire Switzerland-based Senn Chemicals AG

** Co adds, acquisition is expected to close in the

first half of 2025

** Financial details of the deal was not disclosed

** Stock set to log gains after falling for two straight sessions

** Stock down ~14% YTD vs ~13% fall in broader Nifty Pharma index .NIPHARM

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

Feb 21 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA LTD - TO ACQUIRE 100% EQUITY STAKE IN SENN CHEMICALS AG

• GRANULES: DEAL FOR 1.93 BILLION RUPEES

Source text: ID:nNSE1PXl9y

Further company coverage: GRAN.NS

(([email protected];;))

Jan 30 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - FDA APPROVAL FOR LISDEXAMFETAMINE DIMESYLATE CAPSULES

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];))

Jan 29 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT V RECEIVES EU GMP CERTIFICATE

• EU AUTHORITY CONDUCTED AUDIT OF GRANULES INDIA UNIT V IN NOVEMBER 2024

Source text: ID:nBSE5nkvmM

Further company coverage: GRAN.NS

(([email protected];;))

Jan 24 (Reuters) - Granules India Ltd GRAN.NS:

• Q3 CONSOL PROFIT 1.18 BILLION RUPEES

• Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 11.38 BILLION RUPEES

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];;))

** Shares of Granules India GRAN.NS turn positive, up 0.7% at 588.40 rupees

** Pharma co's unit gets US FDA's approval for Lisdexamfetamine Dimesylate chewable tablets, a generic for Vyvanse chewable tablets

** Lisdexamfetamine dimesylate tablets are used to treat attention deficit hyperactivity disorder and binge eating disorder

** Stock was down ~0.5% before disclosure of US FDA approval for unit's drug

** GRAN up ~45% YTD vs gains of 27% in 2023

(Reporting by Vijay Malkar)

(([email protected];))

Dec 4 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - UPDATE ON US FDA INSPECTION AT GAGILLAPUR FACILITY

• GRANULES INDIA LTD - OAI CLASSIFICATION DOES NOT IMPACT ONGOING MANUFACTURING OR DISTRIBUTION

• GRANULES INDIA LTD - OAI STATUS MAY IMPACT REVIEW OF PENDING SUBMISSIONS FOR NEW PRODUCTS

Source text: ID:nnAPN2FLDZF

Further company coverage: GRAN.NS

(([email protected];))

** Shares of pharmaceuticals maker Granules India GRAN.NS close down 10.3%

** This is only the second session this year that the stock has declined by 10% or more

** Stock top loser on the Nifty Pharma index .NIPHARM, which slips about 0.1%

** US FDA classifies inspection co's Gagillapur facility as 'official action indicated' (OAI); the classification means regulatory or administrative actions are recommended

** Co says it has responded to all observations issued by the US FDA and voluntarily undertaken evaluation of facility, in consultation with external subject matter experts

** Trading vols at 18.4 mln, highest since mid-September

** GRAN stock has risen around 32% YTD, NIPHARM also up about 33%

(Reporting by Vijay Malkar)

(([email protected];))

Nov 8 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - GRANULES INDIA’S UNIT V FACILITY SECURES US FDA EIR WITH 'NO ACTION INDICATED' STATUS

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];))

Nov 6 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA Q2 CONSOL PROFIT 972.3 MILLION RUPEES

• GRANULES INDIA Q2 CONSOL TOTAL REVENUE FROM OPERATIONS 9.67 BILLION RUPEES

Further company coverage: GRAN.NS

(([email protected];))

** Shares of Granules India GRAN.NS fall as much as 16.9% to 562.10 rupees, mark sharpest intraday pct loss since March 23, 2020

** Pharmaceutical manufacturing co says several investors have sought clarification from co on U.S. FDA's observations on its Gagillapur facility

** Adds, it will work with FDA to address issues raised in the observations

** On Saturday, FDA inspection at this facility concluded with six observations

** Stock is witnessing its most active trading session since 2005 listing, with more than 35 mln shares change hands, 12.8x of 30-day avg

** Stock last down 16.6%, cutting YTD gains to 39.2%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Aug 20 (Reuters) - Granules India Ltd GRAN.NS:

• RECEIVES ANDA APPROVAL FOR GLYCOPYRROLATE ORAL SOLUTION

Source text for Eikon: ID:nBSE1TgfBl

Further company coverage: GRAN.NS

(([email protected];))

July 30 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES JUNE-QUARTER CONSOL NET PROFIT 1.35 BILLION RUPEES

• GRANULES JUNE-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 11.80 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: GRAN.NS

(([email protected];))

** Indian pharma stocks .NIPHARM up 5.3% this week, set for best weekly rise since March 2022

** Gains led by top-weighted stock Sun Pharma's SUN.NS 9% weekly jump, index heavyweight Divi's Laboratories' DIVI.NS ~6% jump and Torrent Pharma's TORP.NS 6.3% rise

** Granules India GRAN.NS top pct gainer, rising 11.7%, while Biocon BION.NS up 10%

** Eleven stocks on 20-member Nifty Pharma index .NIPHARM rated "buy" or higher, rest rated "hold" - LSEG data

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

** Shares of drugmaker Granules India GRAN.NS fall as much as 2.6% after quarterly results

** Stock trimmed some losses to trade 0.8% lower at 396.3 rupees

** Co said its March-qtr consol rev from ops fell 1.6% to 11.76 bln rupees ($140.9 mln)

** Shares on track to fall for third straight month, after losing 9% in the previous two months

** Trading vol 4.2x the 30-day daily avg, busiest since Feb. 19

** Stock down 2.1% so far in 2024, one of two YTD losers in Nifty Pharma .NIPHARM index

($1 = 83.4770 Indian rupees)

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected] ;))

May 1 (Reuters) - Granules India Ltd GRAN.NS:

• GETS TAX ORDER FOR TOTAL AMOUNT AT 2.1 MILLION RUPEES

Source text for Eikon: ID:nBSE7b5pyJ

Further company coverage: GRAN.NS

(([email protected];))

April 30 (Reuters) - Granules India Ltd GRAN.NS:

• RECEIPT OF ANDA APPROVAL FOR COLCHICINE CAPSULES

• US FDA APPROVED ANDA FILED BY UNIT GRANULES PHARMACEUTICALS, INC FOR COLCHICINE CAPSULES

Source text for Eikon: ID:nBSE4HM7xD

Further company coverage: GRAN.NS

(([email protected];))

April 12 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA LTD - US FDA AUDIT FOR GRANULES INDIA’S UNIT V FACILITY RESULTS IN ZERO 483

Source text for Eikon: ID:nBSE953D8d

Further company coverage: GRAN.NS

(([email protected];))

** Shares of pharmaceutical firm Laurus Labs LAUL.NS rise as much as 7.9% to 448 rupees, highest since Nov. 28, 2022

** Stock on track for fourth consecutive session of gains

** Reuters could not immediately ascertain a reason for the move

** Stock top gainer in Nifty pharma index .NIPHARM, which is trading flat

** Stock most active since Jan. 25; more than 6.9 mln shares change hands by 1:59 p.m. IST, 3.9x the 30-day avg

** Avg rating of 10 analysts equivalent of "hold", median PT is 333 rupees - LSEG data

** Among peers, Granules India GRAN.NS rated "strong buy" while Glenmark Life Sciences GLEM.NS is rated "buy" - LSEG

** LAUL fell 8.8% in March quarter vs 12.9% rise in Nifty pharma index

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

BENGALURU, Jan 23 (Reuters) - Drug maker Granules India GRAN.NS reported a marginal rise in third-quarter profit on Tuesday, helped by easing raw material costs.

The company's consolidated profit rose 1.6% to 1.26 billion rupees (nearly $15 million), according to an exchange filing.

Granules has seen slowing profit growth since the third quarter of 2022. It reported a fall in profit for the past two quarters as it grappled with soaring costs.

The company reported a 0.6% climb in expenses for the third quarter, helped by a 7% fall in raw material costs. In contrast, expenses ranged between 9% and 17% in the last four quarters.

This resulted in a flat profit margin year-on-year at 11%.

Revenue rose 1% to 11.56 billion rupees, with the fixed dosages segment contributing 66% to the total.

Granules, which focuses on making active pharmaceutical ingredients (API), holds 30% of the global market for Paracetamol. It makes the drug's API and finished dosage, the ready-for-consumption product.

Shares of the company rose as much as 3.2% after the results before paring some gains to trade 2.9% higher.

They climbed about 14% in the December quarter, outperforming a 9% rise in the Nifty Pharma index .NIPHARM.

Rival Glenmark Life Sciences GLEM.NS is also expected to report its third-quarter results on Tuesday.

($1 = 83.0900 Indian rupees)

(Reporting by Manvi Pant and Kashish Tandon in Bengaluru; Editing by Sonia Cheema)

(([email protected]; +918447554364;))

Dec 13 (Reuters) - Granules India Ltd GRAN.NS:

• RECEIVED ANDA APPROVAL FOR PANTOPRAZOLE SODIUM DELAYED- RELEASE TABLETS

Source text for Eikon: ID:nBSE43McLm

Further company coverage: GRAN.NS

(([email protected];))

** Shares of drugmaker Granules India GRAN.NS rises 4.6% at 387.2 rupees, their highest level since Aug 2021

** Stock sees most active day in more than two months

** A reason for the move could not be immediately ascertained

** GRAN has closed more than 4.5% up only twice this year

** In the last three months, stock up over 31% vs 4% rise in Nifty Pharma index.NIPHARM

(Reporitng by Nishit Navin)

(([email protected];))

Nov 23 (Reuters) - Granules India Ltd GRAN.NS:

• GOT ORDER FROM GST AUTHORITES DIRECTING CO TO PAY TAX, INTEREST, PENALTY WORTH 4.3 MILLION RUPEES

• NO MATERIAL IMPACT ON COMPANY DUE TO TAX LIABILITY AND PENALTY

Source text for Eikon: ID:nBSE2z98Qz

Further company coverage: GRAN.NS

(([email protected];))

BENGALURU, Nov 9 (Reuters) - Granules India GRAN.NS reported a 3.4% rise in second-quarter revenue on Thursday as the Paracetamol maker benefited from higher sales in North America.

The generic drug maker's consolidated revenue from operations climbed to 11.89 billion rupees ($142.77 million) in the three months ended Sept.30, from 11.51 billion rupees a year earlier.

Indian generic drug makers are expected to gain from new product launches and easing price competition in the United States, which accounts for the bulk of their revenue, according to analysts.

Revenue from North America, the company's biggest market, grew 11% to 7.99 billion rupees, but declined 8% in Europe to 2.13 billion rupees.

Shares of Granules India rose as much as 5% to 374.80 rupees after the results.

The drug maker's net profit, however, dropped nearly 30% to 1.02 billion rupees ($12.25 million) from 1.45 billion rupees as total expenses rose 9.3%.

Granules' three main segments, which focus on making active pharmaceutical ingredients (API), pharmaceutical formulation intermediates and finished dosages, accounted for 25%, 12%, and 62%, respectively, of revenue from operations.

The company, which holds a 30% share of the global market for Paracetamol, makes the drug's API and finished dosage, ready for consumption in European countries.

Its shares gained 19.5% in the September-quarter, outperforming the Nifty pharma index .NIPHARM, which climbed 12%.

Rival Glenmark Life Sciences GLEM.NS last month reported an 11.1% rise in second-quarter profit.

(Reporting by Rama Venkat in Bengaluru; Editing by Sonia Cheema)

(([email protected]; https://twitter.com/ramavenkat0607; +91 8095218099;))

BENGALURU, Oct 6 (Reuters) - Shares of Indian pharmaceutical company Valiant Laboratories VALO.NS rose 15.8% in their trading debut on Friday, valuing the company at 5.28 billion rupees ($63.5 million).

The initial public offering of the Mumbai-based maker of paracetamol tablets was oversubscribed 29.8 times, with retail investors bidding 16 times and high net-worth investors 73.6 times.

The offering had fresh issue of shares worth 1.62 billion rupees ($19.5 million) at the top end of the 133-140 rupees price range.

Valiant is involved in the business of manufacturing active pharmaceutical ingredients (API) for pain killer drug Paracetamol.

Valiant competes with larger rivals such as Granules GRAN.NS and Glenmark Life Sciences GLEM.NS in the API market.

Earlier this week, Indian commercial port operator JSW Infrastructure's JSWN.NS listing saw a bumper opening with shares surging more than 32%.

($1 = 83.2025 Indian rupees)

(Reporting by Sethuraman NR and Kashish Tandon in Bengaluru; Editing by Sohini Goswami)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

** India's Nifty Pharma index .NIPHARM rises as much as 1.36% to 15,185.50 points, its biggest intraday jump since Sept 12

** The index lost nearly 4% in the last six sessions, its longest losing streak since mid-Jan

** Shares of Granules India GRAN.NS, Dr. Reddy's Laboratories REDY.NS, Cipla CIPL.NS, Gland Pharma GLAD.NS among top Nifty pharma gainers on Wednesday after climbing between 2% and 5%

** "We are seeing respite in the pharma index today, a break above 15,250 in the index may prompt further recovery," says Ajit Mishra, senior vice-president for research, Religare Broking

** Including session's gains, Nifty Pharma up 20.4% YTD, versus blue-chip Nifty 50 index .NSEI, which climbed 8.7%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Aug 24 (Reuters) - Granules India Ltd GRAN.NS:

• RECEIVED ACCREDITATION CERTIFICATE OF FOREIGN DRUG MANUFACTURER FROM PMDA

Source text for Eikon: ID:nNSE8JkDF8

Further company coverage: GRAN.NS

(([email protected];))